Camilla Qvortrup

Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective consortium analysis

Wendy De Roock, Bart Claes, David Bernasconi et al. · The Lancet Oncology · 2010 · 2.1K citations

Medicine, Oncology, Pharmacology +13

Global cancer control: responding to the growing burden, rising costs and inequalities in access

Sofía Braga, Branislav Bystrický, Camilla Qvortrup et al. · ESMO Open · 2018 · 314 citations · Full text

Public Health, Health Policy, Oncology +17

TAS-102 with or without bevacizumab in patients with chemorefractory metastatic colorectal cancer: an investigator-initiated, open-label, randomised, phase 2 trial

Per Pfeiffer, Mette Yilmaz, Sören Möller et al. · The Lancet Oncology · 2020 · 231 citations

Medicine, Oncology, Pharmacology +10

Professional burnout in European young oncologists: results of the European Society for Medical Oncology (ESMO) Young Oncologists Committee Burnout Survey

Susana Banerjee, Raffaele Califano, J. Corral et al. · Annals of Oncology · 2017 · 141 citations · Full text

Medicine, Oncology, Adolescent Health +11

Clinical trial enrollment, patient characteristics, and survival differences in prospectively registered metastatic colorectal cancer patients

Halfdan Sørbye, Per Pfeiffer, Nina Cavalli‐Björkman et al. · Cancer · 2009 · 133 citations · Full text

Medicine, Oncology, Chemotherapy +14